Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Nolpitantium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 3/20 | 0.61 |
| ▸ | TACR2 | P21452 | 3/20 | 0.61 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolpitantium SCHEMBL29721569 | 1.00 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29405138 | 1.00 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL7561842 | 1.00 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL2142512 | 0.99 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29388081 | 0.99 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL6350205 | 0.99 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL157084 | 0.94 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29457709 | 0.94 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| Hydrochloric Acid SCHEMBL29907320 | 0.91 | TACR2 (0.50) | TACR2TACR1CCR5 | |
| SCHEMBL8969597 | 0.87 | TACR2 (0.53) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082625-A1 | NOVEL THERAPY | SELECTIMMUNE PHARMA AB (SE) | 2025-03-13 | — | — | US | claimed |
| EP-3481396-B1 | THERAPY OF BACTERIAL INFECTIONS. | SELECTIMMUNE PHARMA AB (SE) | 2023-05-31 | — | — | EP | claimed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | claimed |
| US-20200155534-A1 | NOVEL THERAPY | LINNANE PHARMA AB (SE) | 2020-05-21 | — | — | US | claimed |
| EP-0786988-B1 | USE OF NK1 RECEPTOR ANTAGONISTS FOR PREPARING CARDIO-REGULATORY DRUGS | SANOFI SYNTHELABO (FR) | 2003-05-02 | — | — | EP | claimed |
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | claimed |
| US-6284277-B1 | NONPROTEIN | SANOFI-SYNTHELABO (FR) | 2001-09-04 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| US-20250082625-A1 | NOVEL THERAPY | SELECTIMMUNE PHARMA AB (SE) | 2025-03-13 | — | — | US | disclosed |
| EP-3481396-B1 | THERAPY OF BACTERIAL INFECTIONS. | SELECTIMMUNE PHARMA AB (SE) | 2023-05-31 | — | — | EP | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200155534-A1 | NOVEL THERAPY | LINNANE PHARMA AB (SE) | 2020-05-21 | — | — | US | disclosed |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2015-10-01 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-6284277-B1 | NONPROTEIN | SANOFI-SYNTHELABO (FR) | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885TACR2 179/4885CCR5 2501/4885 |
| US-20150272927-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885TACR2 179/4885CCR5 2501/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885TACR2 179/4885CCR5 2501/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | TACR1 226/4885TACR2 179/4885CCR5 2501/4885 |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | TACR1 12/4885TACR2 44/4885CCR5 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.